docetaxel anhydrous has been researched along with Carcinoma, Ovarian Epithelial in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 35 (87.50) | 24.3611 |
| 2020's | 5 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, Y; Huang, Y; Liu, C; Xu, B; Zhao, C | 1 |
| Andrade, MF; Bowers, RR; Delaney, JR; Jones, CM; Voelkel-Johnson, C; White-Gilbertson, S | 1 |
| Boere, I; Gennigens, C; Hanssen, R; Jalving, M; Ledermann, J; Mathijssen, RHJ; Ottevanger, P; Rijcken, CJF; van de Wouw, YJ; Vergote, I | 1 |
| Cui, M; Cui, S; Jia, Y; Jia, Z; Li, Z; Wang, L; Xu, T | 1 |
| Fan, R; Fletcher, NM; Harper, AK; Morris, RT; Saed, GM | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Diamond, MP; Fletcher, NM; Gomez-Lopez, N; Memaj, I; Morris, RT; Saed, GM | 1 |
| Chen, WM; Liu, EL; Mi, RR; Wang, DH; Wang, LQ; Zhang, YM | 1 |
| Qiang, JW; Qiao, TK; Yuan, SJ | 1 |
| Li, H; Li, X; Lv, M; Qiao, B | 1 |
| Cai, SQ; Qiang, JW; Qiao, TK; Yuan, SJ | 1 |
| Cai, S; Cai, Y; Cheng, X; Dai, Z; Jia, H; Jiang, R; Luan, Y; Pu, H; Shi, T; Tang, J; Tu, D; Tu, R; Wang, H; Yang, H; Zang, R; Zhang, Y | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Apte, SM; Gonzalez-Bosquet, J; Havrilesky, LJ; Herschberger, A; Judson, PL; Lancaster, JM; Lapolla, J; Lin, HY; Secord, AA; Wenham, RM | 1 |
| Alvarez, RD; Anwer, K; Chu, C; Fewell, JG; Kelly, FJ; Lewis, D | 1 |
| Bell, MC; Braly, P; Childs, BH; Drake, RD; Einstein, MH; Herzog, TJ; Hines, JF; Monk, BJ; Roman, LD; Rose, PG; Secord, AA; Wenham, RM | 1 |
| Christopoulou, A; Emmanouilidis, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Koinis, F; Papadimitraki, E; Polyzos, A; Samonis, G; Zafeiriou, Z | 1 |
| Barron, R; Chandler, DB; Fust, K; Li, X; Lyman, GH; Maschio, M; Parthan, A; Walli-Attaei, M; Weinstein, MC | 1 |
| Anderson, GL; Bonebrake, AJ; Chambers, SK; Coleman, RL; Delmore, JE; Hu, W; Markman, M; Moon, J; Sood, AK | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Li, X; Li, Y | 1 |
| DePoint Christensen, R; Havsteen, H; Herrstedt, J; Kristensen, G; Lund, B; Maenpaa, J; Mirza, MR; Wang, Y | 1 |
| Arts, H; de Munck, L; de Vries, E; Hollema, H; Hospers, G; Reyners, A; Timmer-Bosscha, H; van der Marel, P; van Kruchten, M | 1 |
| Belotte, J; Diamond, MP; Fletcher, NM; Memaj, I; Nusrat, O; Saed, GM; Saed, MG | 1 |
| Alvarez, RD; Becker, DA; Bevis, KS; Boone, JD; Gilbert, AL; Huh, WK; Leath, CA; Straughn, JM; Thomas, ED | 1 |
| Liu, CC; Lu, Y; Tang, H; Wang, H; Zhu, J | 1 |
| Concin, N; Koelbl, H; Nehoda, R; Polterauer, S; Reinthaller, A; Seebacher, V | 1 |
| Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK | 1 |
| Buekers, TE; Fracasso, PM; Kunos, CA; Mohiuddin, M; Schilder, JM; Sill, MW; Waggoner, SE; Walker, JL; Yamada, SD | 1 |
| Fauci, JM; Frederick, PJ; Kilgore, LC; Schneider, KE; Straughn, JM; Subramaniam, A; Whitworth, JM; Zhang, B | 1 |
| Ardisson, P; Asmane, I; Bajard, A; Bergerat, JP; Coeffic, D; Dufresne, A; Guastalla, JP; Kurtz, JE; Labidi Galy, I; Meeus, P; Moullet, I; Ray-Coquard, I; Tredan, O; Vincent, L | 1 |
| Bangshöj, R; Boman, K; Graflund, M; Horvath, G; Lood, M; Malmström, H; Nygren, L; Sorbe, B; Swahn, M | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Hao, Y; Iwamori, M; Lin, B; Liu, J; Liu, Q; Zhang, F; Zhang, S; Zhao, Y; Zhu, L | 1 |
| Bangshöj, R; Boman, K; Graflund, M; Horvath, G; Lood, M; Malmström, H; Sorbe, B; Swahn, M | 1 |
| Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK | 1 |
| de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Chang, L; Chao, H; Graham, PH; Hao, J; Kearsley, JH; Li, Y; Ni, J; Wang, L | 1 |
| Cao, Y; Han, Y; Huang, H; Qu, L; Shou, C; Xiao, Z; Zhang, W | 1 |
17 trial(s) available for docetaxel anhydrous and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Docetaxel; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Young Adult | 2023 |
Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites.
Topics: Administration, Intravenous; Aged; Alzheimer Disease; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blood Loss, Surgical; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Operative Time; Ovarian Neoplasms; Survival Rate; Taxoids | 2017 |
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Docetaxel; Etoposide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Progression-Free Survival; Proportional Hazards Models; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids | 2013 |
Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer.
Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chills; Docetaxel; Dysgeusia; Female; Fever; Genetic Therapy; Humans; Hypotension; Interleukin-12; Middle Aged; Nausea; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Plasmids; Taxoids | 2013 |
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Taxoids | 2014 |
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Salvage Therapy; Taxoids | 2014 |
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Quinazolines; Taxoids; Treatment Outcome | 2014 |
[Clinical study on chemotherapy of lobaplatin combined with docetaxel in patients with relapsed ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclobutanes; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids | 2014 |
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Somatosensory Disorders; Taxoids; Treatment Outcome; Young Adult | 2014 |
Hormone receptors as a marker of poor survival in epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Celecoxib; Docetaxel; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prognosis; Prospective Studies; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Tissue Array Analysis | 2015 |
Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Taxoids; Treatment Outcome | 2011 |
A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Nervous System Diseases; Ovarian Neoplasms; Prospective Studies; Quality of Life; Survival Rate; Taxoids | 2012 |
Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Grading; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Phosphorylcholine; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Taxoids | 2012 |
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrazoles; Sulfonamides; Taxoids | 2012 |
23 other study(ies) available for docetaxel anhydrous and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
Effect of docetaxel on mechanical properties of ovarian cancer cells.
Topics: Actin Cytoskeleton; Actins; Carcinoma, Ovarian Epithelial; Cell Survival; Cytoskeleton; Docetaxel; Female; Humans; Microtubules; Ovarian Neoplasms | 2021 |
Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs).
Topics: Apoptosis; Autophagy; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Docetaxel; Female; Giant Cells; Humans; Hydroxychloroquine; Nelfinavir; Ovarian Neoplasms; Polyploidy; Sirolimus | 2022 |
Long-term multidisciplinary integrative therapy management resulted in favorable outcomes for ovarian cancer during pregnancy: a case report and literature review.
Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Combined Modality Therapy; Cytoreduction Surgical Procedures; Docetaxel; Female; Humans; Ovarian Neoplasms; Pregnancy; Pregnancy Complications; Treatment Outcome | 2019 |
Heat Shock Protein 60 (HSP60) Serves as a Potential Target for the Sensitization of Chemoresistant Ovarian Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Chaperonin 60; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Mitochondrial Proteins; Ovarian Neoplasms; RNA, Messenger | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Apoptosis; Carcinoma, Ovarian Epithelial; CD11b Antigen; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Epithelial Cells; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Oxidative Stress; Peroxidase; Taxoids; Xenograft Model Antitumor Assays | 2018 |
Diffusion-weighted imaging and diffusion kurtosis imaging for early evaluation of the response to docetaxel in rat epithelial ovarian cancer.
Topics: Animals; Apoptosis; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Diffusion Magnetic Resonance Imaging; Docetaxel; Female; Ki-67 Antigen; Necrosis; Proto-Oncogene Proteins c-bcl-2; Rats, Sprague-Dawley; ROC Curve; Tumor Burden | 2018 |
Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer.
Topics: Adenosine; Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Disease Models, Animal; Docetaxel; Female; Humans; Mice; Tetraspanins | 2019 |
Dynamic contrast enhanced‑magnetic resonance imaging for the early evaluation of the response to docetaxel in rats with epithelial ovarian cancer.
Topics: Animals; Carcinoma, Ovarian Epithelial; Contrast Media; Disease Models, Animal; Docetaxel; Female; Humans; Magnetic Resonance Imaging; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley | 2019 |
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Taxoids; Topotecan | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Resistance; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Taxoids | 2016 |
The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Multivariate Analysis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Taxoids | 2017 |
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors; Taxoids; Young Adult | 2011 |
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Intestinal Fistula; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Rectovaginal Fistula; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Fistula; Vascular Endothelial Growth Factor A; Vinblastine; Vinorelbine | 2011 |
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2013 |
Increase in docetaxel-resistance of ovarian carcinoma-derived RMG-1 cells with enhanced expression of Lewis Y antigen.
Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fucosyltransferases; Galactoside 2-alpha-L-fucosyltransferase; Gene Expression Regulation, Neoplastic; Humans; Lewis Blood Group Antigens; Microscopy, Electron, Transmission; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Taxoids; Transfection | 2011 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Caspase 3; Cell Line, Tumor; Cell Proliferation; DNA Repair; Docetaxel; Dose-Response Relationship, Drug; Female; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panobinostat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Taxoids | 2013 |
Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Blood Proteins; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Regulatory Networks; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Principal Component Analysis; ROC Curve; Taxoids; Transcriptome | 2012 |